Background Orthostatic hypotension (OH) is a common cause of falls, and key source of morbidity and mortality due to injury (e.g. hip fracture). Current guidelines recommend increasing salt intake in patients with symptomatic orthostatic hypotension. However, the evidence underpinning this recommendation is poor, based primarily on small trials with very short-term follow-up (\< 6 weeks). Clinical Equipoise (Overall) High salt intake might improve quality of life and reduce the risk of falls, but might also increase the risk of cardiovascular disease, in patients with OH. Specific Objective of Current Application (Aim) To determine feasibility (recruitment, retention and adherence) of conducting a randomized controlled trial evaluating high salt intake in older adults with symptomatic orthostatic hypotension. To determine preliminary estimates of the effect of high salt intake on disease-specific quality of life, orthostatic blood pressure (BP) parameters, and cardiac blood biomarkers. Design: Phase IIa, parallel, double-blind, randomised controlled, single centre clinical trial of 12 month follow-up duration. Population: Older adults (≥65 years of age) with an objective diagnosis of symptomatic orthostatic hypotension Intervention: The intervention will be 5g/day of salt supplementation in the form of encapsulated sodium chloride. Outcome measures: Primary outcome (Feasibility) recruitment and retention rates, adherence with intervention and study protocol, completeness of follow-up. Secondary Outcome (Efficacy): i) clinical: change in Orthostatic Hypotension Questionnaire score, modification/addition of OH pharmacotherapy, and falls events, ii) physiological measures of orthostasis: change in difference between supine and nadir systolic BP, standing BP at 1 minute, 24 hour mean BP measured by 24 hour ambulatory BP monitor, iii) cardiovascular biomarkers. Clinical Importance: A recommendation for long-term increases in salt intake may have adverse cardiovascular consequences, which necessitates the identification of the optimal range of salt intake associated with greatest reduction in falls risk and lowest cardiovascular risk. Our study will provide preliminary evidence of treatment effect and assess feasibility, to inform a definitive trial.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
42
A high salt intake range will be achieved through unchanged dietary intake and supplementary salt in the form of 1.25g sodium chloride capsules at a dose of 5g/day in two divided doses
Clinical Research Facility Galway/Galway University Hospital
Galway, Ireland
Recruitment to target (primary feasibility outcome)
Recruitment of 48 participants
Time frame: 15 months
Change in orthostatic hypotension questionnaire score (primary efficacy outcome)
Change in symptoms and quality of life measured using disease specific questionnaire; Orthostatic Hypotension Questionnaire (OHQ) from baseline to final follow-up. All questionnaire items are scored 0 through 10 (higher scores = worse).
Time frame: 6 months
Change in individual components of OHQ from baseline to final follow-up
Change in individual components of OHQ from baseline to final follow-up. All questionnaire items are scored 0 through 10 (higher scores = worse).
Time frame: 6 months
Rates of modification/addition of OH pharmacotherapy
Rates of modification/addition of OH pharmacotherapy
Time frame: 6 months
Rates of modification/addition of anti-hypertensive therapy
Rates of modification/addition of anti-hypertensive therapy
Time frame: 6 months
Falls events
Number of falls events
Time frame: 6 months
Change in difference between supine and nadir blood pressure from baseline to final in-person follow-up
Change in difference between supine and nadir blood pressure from baseline to final in-person follow-up
Time frame: 6 months
Change in standing BP at one minute and three minutes
Change in standing BP at one minute and three minutes measured at active stand
Time frame: 6 months
Change in mean BP measured by 24 hour ambulatory BP monitor
Change in mean BP measured by 24 hour ambulatory BP monitor
Time frame: 6 months
Change in cardiovascular biomarkers; proBNP and troponin
Change in cardiovascular biomarkers; proBNP and troponin
Time frame: 6 months
Change in formula derived 24 hour urinary sodium from baseline to final in-person follow-up visit.
Change in formula derived 24 hour urinary sodium
Time frame: 6 months
Change in renin-aldosterone ratio from baseline to final in-person follow-up visit.
Change in renin-aldosterone ratio from baseline to final in-person follow-up visit.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.